392 material Form 8-K filings that 341 companies we cover made with the SEC in July 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Portland General Electric reported second-quarter 2024 GAAP net income of $72 million, or $0.69 per diluted share, up from $39 million, or $0.39, a year earlier, and total revenues of $758 million versus $648 million. The company reaffirmed its full-year 2024 adjusted earnings guidance of $2.98 to $3.18 per diluted share and set up a new at-the-market stock sale program of up to $400 million, which could add shares outstanding.
Q2 2024 GAAP net income of $72 million ($0.69 per diluted share) vs. $39 million ($0.39) in Q2 2023
Total revenues of $758 million vs. $648 million in Q2 2023; total operating expenses rose to $642 million from $567 million
2024 adjusted EPS guidance of $2.98 to $3.18 reaffirmed, not changed
New at-the-market common stock offering program registered July 26, 2024, for up to $400 million; agents receive commissions of up to 2% of gross sales price
Saia reported second quarter 2024 results with revenue of $823.2 million, up 18.5%, and diluted earnings per share of $3.83, up from $3.42 a year earlier. Operating ratio worsened to 83.3% from 82.7%, and management said it expects net capital expenditures of about $1 billion in 2024.
Operating income was $137.6 million, a 14.4% increase from the second quarter of 2023.
Operating ratio was 83.3%, compared with 82.7% a year earlier.
Net capital expenditures were $681.3 million in the first six months of 2024, and the company expects about $1 billion for the full year.
Cash on hand was $11.2 million and total debt was $176.7 million at June 30, 2024.
Colgate-Palmolive reported second quarter 2024 net sales of $5,058 million, up 4.9%, and GAAP diluted EPS of $0.89, up 48% from $0.60. The company raised its full-year 2024 organic sales growth guidance to 6% to 8% and its Base Business EPS growth guidance to 8% to 11%.
Organic sales grew 9.0% in the quarter; Base Business EPS rose 18% to $0.91
GAAP gross profit margin rose 280 basis points to 60.6%
Full-year 2024 organic sales growth guidance raised to 6% to 8% from 5% to 7%
Net sales growth guidance of 2% to 5% unchanged, including a mid-single-digit negative foreign exchange impact
Balchem reported second quarter 2024 results for the period ended June 30, 2024, with net sales of $234.1 million, up 1.2%, and GAAP net earnings of $32.1 million, up 6.5%. Adjusted EBITDA was a record $62.3 million, up 5.0%, but the Animal Nutrition and Health segment's sales and earnings from operations fell sharply, which partly offset growth in the other two segments.
GAAP diluted earnings per share were $0.98, compared with $0.93 a year earlier; adjusted earnings per share were $1.09, compared with $1.06.
Human Nutrition and Health sales rose 9.0% to $147.9 million, and Specialty Products sales rose 7.2% to $35.1 million.
Animal Nutrition and Health sales fell 19.2% to $49.6 million, and its earnings from operations fell 64.9% to $2.7 million.
Free cash flow was $38.4 million, and the company repaid $35.0 million on its revolving debt, bringing net debt to $202.8 million.
T. Rowe Price reported second-quarter 2024 results on July 26, 2024, with net revenues of $1.7 billion, up 7.6% from a year earlier, and diluted earnings per share of $2.11, up 2.4% from a year earlier. The firm also recorded net client outflows of $3.7 billion, and both revenue and GAAP earnings fell from the first quarter of 2024.
Net revenues were $1,733.3 million in Q2 2024, up 7.6% from Q2 2023 and down 1.0% from Q1 2024.
GAAP diluted EPS was $2.11 versus $2.06 a year earlier and $2.49 in Q1 2024; adjusted diluted EPS was $2.26.
Ending assets under management were $1.57 trillion at June 30, 2024, after net client outflows of $3.7 billion in the quarter.
The firm returned $396 million to stockholders through dividends and stock repurchases in the quarter.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.